Cyprus Based Berhyanda News Today

Suven Pharmaceuticals Ltd had reported a 12.2 percent year-on-year (YoY) rise in net profit at Rs 120.6 crore for the first quarter that ended June 30, 2023

Suven Pharmaceuticals Ltd had reported a 12.2 percent year-on-year (YoY) rise in net profit at Rs 120.6 crore for the first quarter that ended June 30, 2023

According to the latest shareholding pattern available with the exchanges, as of 30 June 2023, 60% of the companys shareholding is with the promoter & promoter group, and 40% with the public.

Suven Pharmaceuticals shares zoomed 8.53% to a fresh high of Rs 557.40 against the previous close of Rs 513.55 on BSE

The approval is for acquisition of up to 76.1% shares of Suven Pharmaceuticals by Berhyanda Limited.

(This story has not been edited by THE WEEK and is auto-generated from a PTI

The approval is for acquisition of up to 76.1 per cent shares of Suven Pharmaceuticals by Berhyanda by way of transfer of shares from existing promoter shareholders and public shareholders.

The government on Wednesday approved a foreign investment of up to ₹9,589 crore in Suven Pharmaceuticals by Cyprus-based Berhyanda Ltd. Representational Image The

The approval is for acquisition of up to 76.1 per cent shares of Suven Pharmaceuticals by Berhyanda by way of transfer of shares from existing promoter shareholders and public shareholders through mandatory open offer

The government on Wednesday approved foreign direct investment of up to Rs 9,589 crore in Suven Pharmaceuticals Ltd. by Cyprus-base Berhyanda Ltd. The approval is for the acquisition of up to 76.1% of the equity shares of Suven Pharma by Berhyanda Ltd., based in Cyprus, according to a release by the Cabinet Committee on Economic Affairs on Wednesday. This would bring the total foreign investment to 90.1% in Suven Pharma.